80 related articles for article (PubMed ID: 9218871)
1. Transcriptional defects underlie loss of E-cadherin expression in breast cancer.
Ji X; Woodard AS; Rimm DL; Fearon ER
Cell Growth Differ; 1997 Jul; 8(7):773-8. PubMed ID: 9218871
[TBL] [Abstract][Full Text] [Related]
2. Extinction of E-cadherin expression in breast cancer via a dominant repression pathway acting on proximal promoter elements.
Hajra KM; Ji X; Fearon ER
Oncogene; 1999 Dec; 18(51):7274-9. PubMed ID: 10602481
[TBL] [Abstract][Full Text] [Related]
3. Beta- and gamma-catenin mutations, but not E-cadherin inactivation, underlie T-cell factor/lymphoid enhancer factor transcriptional deregulation in gastric and pancreatic cancer.
Caca K; Kolligs FT; Ji X; Hayes M; Qian J; Yahanda A; Rimm DL; Costa J; Fearon ER
Cell Growth Differ; 1999 Jun; 10(6):369-76. PubMed ID: 10392898
[TBL] [Abstract][Full Text] [Related]
4. Promoter methylation regulates cadherin switching in squamous cell carcinoma.
Chen Q; Lipkina G; Song Q; Kramer RH
Biochem Biophys Res Commun; 2004 Mar; 315(4):850-6. PubMed ID: 14985090
[TBL] [Abstract][Full Text] [Related]
5. E-cadherin expression is silenced by DNA hypermethylation in human breast and prostate carcinomas.
Graff JR; Herman JG; Lapidus RG; Chopra H; Xu R; Jarrard DF; Isaacs WB; Pitha PM; Davidson NE; Baylin SB
Cancer Res; 1995 Nov; 55(22):5195-9. PubMed ID: 7585573
[TBL] [Abstract][Full Text] [Related]
6. Aberrant methylation and silencing of ARHI, an imprinted tumor suppressor gene in which the function is lost in breast cancers.
Yuan J; Luo RZ; Fujii S; Wang L; Hu W; Andreeff M; Pan Y; Kadota M; Oshimura M; Sahin AA; Issa JP; Bast RC; Yu Y
Cancer Res; 2003 Jul; 63(14):4174-80. PubMed ID: 12874023
[TBL] [Abstract][Full Text] [Related]
7. Loss of expression and aberrant methylation of the CDH13 (H-cadherin) gene in breast and lung carcinomas.
Toyooka KO; Toyooka S; Virmani AK; Sathyanarayana UG; Euhus DM; Gilcrease M; Minna JD; Gazdar AF
Cancer Res; 2001 Jun; 61(11):4556-60. PubMed ID: 11389090
[TBL] [Abstract][Full Text] [Related]
8. CpG methylation as a basis for breast tumor-specific loss of NES1/kallikrein 10 expression.
Li B; Goyal J; Dhar S; Dimri G; Evron E; Sukumar S; Wazer DE; Band V
Cancer Res; 2001 Nov; 61(21):8014-21. PubMed ID: 11691827
[TBL] [Abstract][Full Text] [Related]
9. Frequent alterations in E-cadherin and alpha- and beta-catenin expression in human breast cancer cell lines.
Pierceall WE; Woodard AS; Morrow JS; Rimm D; Fearon ER
Oncogene; 1995 Oct; 11(7):1319-26. PubMed ID: 7478552
[TBL] [Abstract][Full Text] [Related]
10. Elevation of breast carcinoma Nm23-H1 metastasis suppressor gene expression and reduced motility by DNA methylation inhibition.
Hartsough MT; Clare SE; Mair M; Elkahloun AG; Sgroi D; Osborne CK; Clark G; Steeg PS
Cancer Res; 2001 Mar; 61(5):2320-7. PubMed ID: 11280805
[TBL] [Abstract][Full Text] [Related]
11. 5' CpG island methylation of the FHIT gene is correlated with loss of gene expression in lung and breast cancer.
Zöchbauer-Müller S; Fong KM; Maitra A; Lam S; Geradts J; Ashfaq R; Virmani AK; Milchgrub S; Gazdar AF; Minna JD
Cancer Res; 2001 May; 61(9):3581-5. PubMed ID: 11325823
[TBL] [Abstract][Full Text] [Related]
12. Downregulation in vivo of the invasion-suppressor molecule E-cadherin in experimental and clinical cancer.
Mareel M; Vleminckx K; Vermeulen S; Yan G; Bracke M; van Roy F
Princess Takamatsu Symp; 1994; 24():63-80. PubMed ID: 8983064
[TBL] [Abstract][Full Text] [Related]
13. Metastasis tumor antigen family proteins during breast cancer progression and metastasis in a reliable mouse model for human breast cancer.
Zhang H; Stephens LC; Kumar R
Clin Cancer Res; 2006 Mar; 12(5):1479-86. PubMed ID: 16533771
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of p53 represses E-cadherin expression by increasing DNA methyltransferase-1 and promoter methylation in serous borderline ovarian tumor cells.
Cheng JC; Auersperg N; Leung PC
Oncogene; 2011 Sep; 30(37):3930-42. PubMed ID: 21478913
[TBL] [Abstract][Full Text] [Related]
15. Four human breast cancer cell lines with biallelic inactivating alpha-catenin gene mutations.
Hollestelle A; Elstrodt F; Timmermans M; Sieuwerts AM; Klijn JG; Foekens JA; den Bakker MA; Schutte M
Breast Cancer Res Treat; 2010 Jul; 122(1):125-33. PubMed ID: 19763817
[TBL] [Abstract][Full Text] [Related]
16. P-cadherin overexpression is an indicator of clinical outcome in invasive breast carcinomas and is associated with CDH3 promoter hypomethylation.
Paredes J; Albergaria A; Oliveira JT; Jerónimo C; Milanezi F; Schmitt FC
Clin Cancer Res; 2005 Aug; 11(16):5869-77. PubMed ID: 16115928
[TBL] [Abstract][Full Text] [Related]
17. Altered expression of E-cadherin in hepatocellular carcinoma: correlations with genetic alterations, beta-catenin expression, and clinical features.
Wei Y; Van Nhieu JT; Prigent S; Srivatanakul P; Tiollais P; Buendia MA
Hepatology; 2002 Sep; 36(3):692-701. PubMed ID: 12198663
[TBL] [Abstract][Full Text] [Related]
18. Hypomethylation of the synuclein gamma gene CpG island promotes its aberrant expression in breast carcinoma and ovarian carcinoma.
Gupta A; Godwin AK; Vanderveer L; Lu A; Liu J
Cancer Res; 2003 Feb; 63(3):664-73. PubMed ID: 12566312
[TBL] [Abstract][Full Text] [Related]
19. Progression of carcinoma cells is associated with alterations in chromatin structure and factor binding at the E-cadherin promoter in vivo.
Hennig G; Behrens J; Truss M; Frisch S; Reichmann E; Birchmeier W
Oncogene; 1995 Aug; 11(3):475-84. PubMed ID: 7630631
[TBL] [Abstract][Full Text] [Related]
20. Multiple mechanisms underlie the aberrant expression of the human kallikrein 6 gene in breast cancer.
Pampalakis G; Sotiropoulou G
Biol Chem; 2006 Jun; 387(6):773-82. PubMed ID: 16800739
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
